All News
"If you are throwing a JAKi at these patients (see below) you are gonna make them better." Dr. Bruce Strober reporting on potential patients/disease states who may respond to JAKi. #RNL2024 @RheumNow https://t.co/bghPuszu5t
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2024 @RheumNow
Bruce Strober on JAK in skin diseases - diverse benefits:
- PsO
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Vitiligo
- Lichen planus any many others https://t.co/I9XHVbFpvQ
Eric Dein ericdeinmd ( View Tweet)
“JAKi can be thrown at any inflammatory skin disease and will work!” Dr. B Strober admits he uses many off-label. #RNL2024 @rheumnow https://t.co/nWzW9rMcWL
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
Winthrop on Shingrix:
Good data at 10 yrs
Diminished response in immunocompromised (chemo)
Very limited data with autoimmune patients https://t.co/cJitGOWZQt
Eric Dein ericdeinmd ( View Tweet)
The 10 year Shingrix data showing continued humoral responses in "normal" patients, with continued long-term efficacy (drops to only 70+%) suggesting we may need to boost at some point.
In our rheumatology patients, the efficacy does drop and needs to be evaluated. Dr. Kevin… https://t.co/eHfjtsPv2O https://t.co/K1i5R3ZScV
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow #RNL2024
Winthrop:
JAKi similar for opportunistic disease, but higher risk for Herpes Zoster than other therapies
Deucravacitinib - lower HZ reported, but younger age. Will see if this holds case in more studies https://t.co/Nd5LitAI3R
Links:
Eric Dein ericdeinmd ( View Tweet)
So why should you consider JAKi?
Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety.
#RNL2024 @RheumNow https://t.co/BgFjhb18Ad
Dr. Rachel Tate uptoTate ( View Tweet)
Random effect in ACR20 responses in male versus females in PsA.
No sex differences in ACR20 responses in patients on JAK/TYK2i .
@lihi_eder
#RNL2024
@RheumNow https://t.co/fgEORm0nKc
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Sex/Gender disparities in rheumatology.
@lihi_eder
#RNL2024
@RheumNow https://t.co/PB7zPYJHd0
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
A word on Explicit/ Implicit Bias .
Amazing talk and very insightful.
@lihi_eder
#RNL2024
@RheumNow https://t.co/SGmk5wa9nP
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAKi toxicities of interest:
- Zoster
- Safety: VTE, MACE, Malignancies
- Lab abnormalities including CK, LFT, creatinine, and lipid elevations and cytopenias.
@JointMD #RNL2024
@rheumnow https://t.co/u72yz8uLYB
Dr. Rachel Tate uptoTate ( View Tweet)
@JointMD reviews the pros and cons of JAKi at #RNL2024 @RheumNow https://t.co/z9CSvP5BAZ
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
More evidence to support role of Tyk2 in management
of skin psoriasis.
Dr.April Armstrong
#RNL2024
@RheumNow https://t.co/9vuuhJMj36
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Amazing talk by @lihi_eder on sex differences in PsA.
#RNL2024
@RheumNow https://t.co/PW5fYLYmu5
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Crossed out all therapies that doesn’t work for skin psoriasis.
For some reason, i thought that JAKi s worked for skin psoriasis. Thanks to Dr.Armstrong for clarifying.
#RNL2024
@RheumNow https://t.co/f71qmHGLwm
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
FDA-approved biologics for skin psoriasis by April Armstrong , its always nice to hear from Derm colleagues.
#RNL2024
@RheumNow https://t.co/vTLpOim8Ct
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Impact of obesity on PsA @AlexisOgdie
Weight loss works in PsA:
5 to 10% weight loss lead to OR: 3.7 MDA responses
> 10% of body weight lead even higher odds ( 6.67). #RNL2024
@RheumNow https://t.co/73O0I7uZF4
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Sever psoriatic arthritis / psoriasis by @AlexisOgdie
#RNL2024
@RheumNow https://t.co/KbN7mnHTSd
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Treating dactylitis and enthesitis: this is a sign of aggressive disease. Dr. @AlexisOgdie will treat with high dose NSAIDS and get patients on biologics quickly. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Which IL17i to choose? Depends on the domain
Dr. Armstrong: For the skin, the studies show brodalumab, ixekizumab and bimekizumab are superior to secukimumab for #psoriasis
Dr. @AlexisOgdie noted we don't see much differences in these IL17i for the joints.
#RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)